Search clinical trials for: EVX-02A OR EVX-02B

Total 1347 results

Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ELX-02 in Healthy Adults

Genetic Disease | Nonsense Mutation

Belgium
Eloxx Pharmaceuticals, Inc.

Terminated

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Genetic Diseases | Nonsense Mutations
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Focal Muscular Vibration in Patients With Severe Acquired Brain Injury

Brain Injuries | Spasticity, Muscle

Italy
MediWound Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of EscharEx (EX-02) in the Treatment of Basal Cell Carcinoma

Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Italy, Czechia, Switzerland, Portugal, Austria, Hungary, Norway, Poland
MediWound Ltd

Completed

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

Diabetic Foot Ulcer | Venous Leg Ulcer

United States
Methodist Health System

Active, not recruiting

A Review of External Ventricular Drain Placement at the Bedside Versus Operating Room

External Ventricular Drain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

Cystic Fibrosis

Canada, France, Germany, United Kingdom, Israel, Australia, Spain, Netherlands, Denmark, Switzerland
Eloxx Pharmaceuticals, Inc.

Terminated

A Phase 2 Study of ELX-02 in Patients With Nephropathic Cystinosis

Genetic Disease | Cystinosis | Nonsense Mutation

Canada
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Cystic Fibrosis

United States, Spain, United Kingdom, New Zealand, Israel, Australia, Ireland, Germany, Sweden, Czechia, Portugal, Hungary
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Cystic Fibrosis

United States, United Kingdom, Belgium, Netherlands, France, Denmark, Israel, New Zealand, Australia, Ireland, Sweden, Canada, Germany, Poland, Switzerland, Italy, Austria, Hungary, Greece, Norway
Eloxx Pharmaceuticals, Inc.

Recruiting

A Study of ELX-02 in Patients With Alport Syndrome

Alport Syndrome

United Kingdom, Australia
Eloxx Pharmaceuticals, Inc.
Syneos Health

Completed

A Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics of ELX-02

Impaired Renal Function

United States
Eloxx Pharmaceuticals, Inc.
SGS Life Sciences, a division of SGS Belgium NV

Completed

Phase 1 Study of ELX-02 in Healthy Adult Subjects

Genetic Disease | Nonsense Mutation

Belgium
Vertex Pharmaceuticals Incorporated

Recruiting

Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age

Cystic Fibrosis

United Kingdom, Canada, Australia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and Older

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Not yet recruiting

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
Vertex Pharmaceuticals Incorporated

Approved for marketing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Cystic Fibrosis
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Belgium, Netherlands
Vertex Pharmaceuticals Incorporated

Completed

A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Canada, Denmark, Germany, Italy, Israel
Vertex Pharmaceuticals Incorporated

Active, not recruiting

Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del

Cystic Fibrosis

Spain, Belgium, Netherlands, France, Canada, Germany, Sweden, Switzerland, Italy, Czechia, Portugal, Austria, Hungary, Norway, Poland
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy

Cystic Fibrosis

Belgium, United Kingdom, Australia, Germany
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Immunologic Memory (Supp. of ATN 024)

HIV Infections

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Belgium, Spain, Australia, Canada
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Cystic Fibrosis

United States, United Kingdom, Canada, Australia, Germany
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom, Canada, Australia, France, Germany, Italy, Czechia, Austria, Sweden, Greece
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

France, Spain, Belgium, Netherlands, Australia, Italy, Czechia
University of Erlangen-Nürnberg Medical School
University of Aarhus; Royal College of Surgeons, Ireland; European Commission; Philipps... and other collaborators

Withdrawn

Hybrid Device DIALYTRODE for Multimodal Neuro-monitoring of Patients With Brain Injury and Status Epilepticus

Epilepsy | Brain Injuries

Germany
GTx

Withdrawn

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

ER+ and AR+ Breast Cancer

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Approved for marketing

ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del Mutation

Cystic Fibrosis
Codman & Shurtleff

Completed

Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System

Subarachnoid Hemorrhage | Intraventricular Hemorrhage

France, United States, Hong Kong, Canada, United Kingdom, Singapore, China, Norway
Staar Surgical Company

Completed

Multicenter Clinical Trial of a Phakic Implantable Collamer® Lens (ICL)

Myopia | Myopic Astigmatism

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-985 in Subjects With Chronic Hepatitis C

Chronic Hepatitis C

United States
Vertex Pharmaceuticals Incorporated

Recruiting

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Diabetes Mellitus, Type 1 | Impaired Hypoglycemic Awareness | Severe Hypoglycemia

United States, Norway, Italy, Canada, France, United Kingdom, Switzerland, Netherlands, Germany
MediWound Ltd

Completed

A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers

Venous Leg Ulcer

United States, Switzerland
Sonya Heltshe
University of Alabama at Birmingham; University of Washington; Cystic Fibrosis...

Recruiting

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children (BEGIN)

Cystic Fibrosis

United States
University of California, Los Angeles
University of Iowa; Children's Hospital Colorado; University of Kansas Medical... and other collaborators

Recruiting

Sinus Disease in Young Children With Cystic Fibrosis

Chronic Rhinosinusitis (Diagnosis) | Cystic Fibrosis | Olfactory Disorder | Cystic Fibrosis in Children | Olfactory Impairment

United States
San Francisco Veterans Affairs Medical Center
VA Office of Research and Development

Completed

Brain Aging in Veterans (BRAVE) Training: A Cognitive Training Pilot Trial in Older Veterans With Traumatic Brain Injury

TBI (Traumatic Brain Injury)

United States
Akili Interactive Labs, Inc.

Completed

Software Treatment for Actively Reducing Severity of ADHD (STARS-ADHD)

Attention Deficit Disorder With Hyperactivity

United States
Revogenex, Inc.

Suspended

A Four Arm Study to Evaluate the Safety and Efficacy of 3 Different Doses of RVX-100 Versus Placebo in Subjects With Irritable Bowel Syndrome Accompanied by Diarrhea (IBS-D)

Irritable Bowel Syndrome

United States
Universität des Saarlandes

Completed

Mechanical Recanalization With Flow Restoration in Acute Ischemic Stroke (ReFlow)

Acute Stroke

Germany
Akili Interactive Labs, Inc.

Completed

Software Treatment for Actively Reducing Severity of ADHD - Follow Up (STARS-ADHD2)

Attention Deficit Disorder With Hyperactivity

United States

Search clinical trials for: EVX-02A OR EVX-02B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations